Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds Exane BNP Paribas Downgrades Thomson Reuters to Underperform

Exane BNP Paribas Downgrades Thomson Reuters to Underperform

Exane BNP Paribas analyst Sami Kassab downgrades Thomson Reuters (NYSE:TRI) from Neutral to Underperform.

December 1, 2022

1 minute read

Exane BNP Paribas analyst Sami Kassab downgrades Thomson Reuters (NYSE:TRI) from Neutral to Underperform.

Oppenheimer Initiates Coverage On Revolution Medicines with Outperform Rating, Announces Price Target of $30

October 21, 5:19 AM

Oppenheimer analyst Jay Olson initiates coverage on Revolution Medicines (NASDAQ:RVMD) with a Outperform rating and announces Price Target of $30.

January 9, 5:01 PM

During the last three months, 5 analysts shared their evaluations of ResMed (NYSE:RMD), revealing diverse outlooks from bullish…

June 18, 4:11 PM

The U.S. cannabis market presents a significantly skewed risk-reward opportunity, particularly within the realm of multi-state operators (MSOs).

April 4, 11:01 AM

Over the past 3 months, 5 analysts have published their opinion on Life Storage (NYSE:LSI) stock. These analysts…